Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Piper Jaffray 27th Annual Healthcare Conference (December 2015)

25 slides from Sucampo Pharmaceuticals's conference presentation, Dec 2, 2015

  1. Slide 1: The Science of Innovation

    Slide 1: The Science of Innovation

    $ sucampo he Science of Innovation Piper Jaffray 27'* Annual Healthcare Conference December 2, 2015 Peter Greenleaf Chief Executive Officer

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements $ sucamro This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigatio Ridonm A of 1085 meee Statements cio Based on masiagement'scsvent execetfons and livolis rake end uncertainties, whi sults to differ materially fro

  3. Slide 3: Investment Highlights

    Slide 3: Investment Highlights

    Investment Highlights . iT biop ‘ive R&D (lubiprostone): highly partnering: ophthalmic, i i and oncology disorders Cobiprostone ERD/s\ Top-line data 1H16 . VAP: 4 inhibitor compounds for NASH, COPD to fuel continued transformation

  4. Slide 4: Clear Strategy to Methodically Build a Leading Bio/Pharma Company

    Slide 4: Clear Strategy to Methodically Build a Leading Bio/Pharma Company

    Clear Strategy to Methodically Build a Leading Bio/Pharma e Company 9 SUCAMPO.. Revenue & Market Value a Focus efforts and strengthen overall capabilities Team - Development capability Secure and AMITIZA rayeuten = Ongoing ey of patent litigation Optimize investment in current pipeline Life cycle ma

  5. Slide 5: AMITIZA: Constipation Opportunity

    Slide 5: AMITIZA: Constipation Opportunity

    AMITIZA: tipati $ sucamPo_ %o+ annually (2045) — Few patients aware of chronic Rx options lubiprostone

  6. Slide 6: Market Is Large and Growing

    Slide 6: Market Is Large and Growing

    Market Is L: ing $ sucampo_ Share of Prescription Constipation Products onere Branco Gonere fategy: convert from OT sarees to AMITIZA, > 88% of NRx are new patients ‘Cand _Seute: Wa Ses erearh and Company exists Chronic Idiopathic Constipation (clo) Infrequent and difficult passage of stool over 12

  7. Slide 7: AMITIZA: Broadest Label in Constipation Market

    Slide 7: AMITIZA: Broadest Label in Constipation Market

    AMITIZA: Broadest Label in Constipation Market $ SUCAMPO_ - CIC IBS-C OIC (non-cancer) — Increases intestinal fluid secretion Key product characteristics = Locally-acting — Rapid and predictable onset of action + No black box warning

  8. Slide 8: AMITIZA Prescription Growth Is Accelerating

    Slide 8: AMITIZA Prescription Growth Is Accelerating

    AMITIZA Pr iptior is Accelerati $ SUCAMPO_ August RX YOY growth rates: TRx 10%; NRx 14% U.S. TRx Scripts Japan TRx Scripts) re ‘anal (mess) 22018 1.920 (rousands) aaes 16 1.208 jose ase 4422 WES ‘2006 2007” 2008” 2009” 2010” 2011” 2012” 2013 2oNe UTM a2 errs 218 2012 2018 zou UTMenons 22018 U.S. Net

  9. Slide 9: Blue-Chip Partnerships Provide Global Reach for AMITIZA

    Slide 9: Blue-Chip Partnerships Provide Global Reach for AMITIZA

    Blue-Chip Partnerships Provide Global Reach for AMITIZA $ sucaMPo_ . it Canada, U.K and Switzerland; 800 sales reps in U.S. Key Partnerships (Mylan) and China (Mylan 15, Canad Japan for new formulationsfindications US. Canada, Europe . for North America beginning January 2021 Cx ane «Agreement with

  10. Slide 10: Competitive Overview

    Slide 10: Competitive Overview

    Competitive Overview $ sucampo_ AMITIZA i itic ee sai + Long istry of usage Ry amitiza x Gere, v VY —¥_—_—_8%_ + Weltolerated product than estatished safely profile | (aes by Tokecs) Fey | lubiprostone ‘av kaink. Rosine “aie + Notinitation on curation of use 1 ° ae 7 "Baik Warne Spa DedsneTSe” RM Li

  11. Slide 11: AMITIZA Lifecycle Management

    Slide 11: AMITIZA Lifecycle Management

    AMITIZA Lifecycle Mi $ sucaMPo_ New Formulation patients ~40% of adults have difficulty swallowing pills, Next step: Phase 3, commence 2H16 Takeda to reimburse 100% of development costs + Phase 3 program: — With current capsule formulation: Children 6-17 years + Trial ongoing; Data 2H16 Trial initia

  12. Slide 12: AMITIZA Growth Strategy

    Slide 12: AMITIZA Growth Strategy

    AMITIZA Growth Strategy $ sucampo_ PARTNERSHIPS! “Fu OTU URE REVENUE Y RTU Acquisition increases AMITIZA Y Underpenetrated revenue markets with 7 unsatisfied patients rakeda we Exparwied eked) Teves pH agreer brand Y Physician Targeting ee, Par ¥ ; ‘Agreement Y OIC driving 30% with Par of brand sale

  13. Slide 13: R-Tech Ueno Acquisition Benefits

    Slide 13: R-Tech Ueno Acquisition Benefits

    Benefit $ sucampo_ Company Description Immediately Snicaety 7 AMITIZA Expansion and diversification of product pipeline Significant cost. synergy opportunity pr pr 5 Strong and stable free cash flow manufacturing

  14. Slide 14: Strengthened Financial Position of Combined Company

    Slide 14: Strengthened Financial Position of Combined Company

    Strengthened Financial Position of Combined Company $ sucampo_ Key Products: Areas Number of Marketed Products g 2 2 LTM 6/30/16 : . $63.7M $175.4) mneober ; Sg ‘m Reseva ese Revenue by 1% Product: sautiza aura oe ‘oe umes ner a one over : Tataca S ‘oe ic Revenue by Tekass — Partner gan ee a 2% yan

  15. Slide 15: Product Pipeline Overview

    Slide 15: Product Pipeline Overview

    Product Pipeline Overview Gintaborel inflammation ‘ums 2 Pati tinction conston 3 2016 2017 Curent apse frnlton Luiprostone Hropetele cea Pete tinebona conan, ait ms 207 2018 New iq formulation fermeialon obiprentone NEROWSERO m2 2010 220 Micocheve formation aps 5 ae rvs vert Pt xt Ophthalmology rant

  16. Slide 16: Cobiprostone: Phase 2 Asset in NERD/sGERD

    Slide 16: Cobiprostone: Phase 2 Asset in NERD/sGERD

    Cobiprostone: Phase 2 Asset in NERD/sGERD $ sucamPo_ 20% of U.S. adult population M) * Significant opportunity pee "9 % has NERD/GERD ( ) (sGERD) patients refractory to PPIs relief onl 60% diagnosed (endoscopy; a PPI Incremental opportunity of $500M - $4B Differentiated tight junctions in the epithe

  17. Slide 17: R-Tech Ueno Pipeline

    Slide 17: R-Tech Ueno Pipeline

    R-Tech Ueno Pipeline e 2 SUCAMPO. VAP-1 inhibitors — Enzyme and adhesion receptor COPD. * RTU-1096 * RTU-009 future extension * Opportunity to be best-in-class

  18. Slide 18: Strong Financial Performance and Balance Sheet

    Slide 18: Strong Financial Performance and Balance Sheet

    Strong Financial Perf 1 Bal f $ sucamPo_ + Total revenues up 6% to $33.4M. + Net income = $7.2M. + EPS = $0.16 + Product sales revenue up 20% to $11.0M (excl. 2014 milestone payment) + Operating cash flow = $24.21 Le ‘As of 10/20/15 ‘As of 09/30/15 ‘As of 12/31/14 Cash, Cash Equivalents, $135.0m $26

  19. Slide 19: Upcoming Milestones

    Slide 19: Upcoming Milestones

    Upcoming Milestones Cobiprostone AMITIZA (lubiprostone) AMITIZA (lubiprostone) AMITIZA (lubiprostone) AMITIZA (lubiprostone) AMITIZA (lubiprostone) Cobiprostone AMITIZA (lubiprostone) Event Top-line data from Phase 2 NERD/sGERD Top-lir adults. Top-line data from Pha: pivotal PFC (6-17 years) P (6-17

  20. Slide 20: Investment Highlights

    Slide 20: Investment Highlights

    Investment Highlights . iT biop ‘ive R&D propt y drug: (lubiprostone): highly ophthalmic, i i and oncology disord lers: Cobiprostone: it NERD/sGERD; Top-line data 1H16 VAP-1 inhibitor compounds for NASH, COPD q to fuel continued transformation

  21. Slide 21: Back Up Slides

    Slide 21: Back Up Slides

    Back Up Slides

  22. Slide 22: Patent Overview

    Slide 22: Patent Overview

    Patent Overview $ sucampo_ US. 934 Patent expires 2021 ‘Composition of Matter Composition of Matter (Substance / API) (Product) AMITIZA Therapeutic use Manufacturing USS. 1016, '613, ‘283, 448, (653, ‘481, '312 Latest patent expires, 2024 + AMITIZAi tional 10 patents through i 2027 through 2027 Use

  23. Slide 23: Cobiprostone: Oral Mucositis

    Slide 23: Cobiprostone: Oral Mucositis

    $ sucamPo_ Cobiprostone: Oral Mucositis -5% of all cancers are HNC * Significant opportunity = ~60K U. — More than half treated with radiation — ~550K HNC cases annually worldwide therapies in the U.S. function Differentiated Clinical development DA fast-track designation Phase 2 initiation 2H15

  24. Slide 24: Team

    Slide 24: Team

    Team $ sucampo_ Peter Greenleaf v Peter Klenet, OB Bristol Myers Squibb til Ambrx Zyngenia jet Scientiic Offiar ie Peter Lichtlen, M.D., Ph.D. . — Bon Seg Matthias Ald ‘ = 4 CYTOS micr@met & novarnis pstrazenees 2 a Vivus Iul Baxter y) & werk flare SANOFI Pee Sanlcy ME Ey sata, oe IWIN, Abbott Prssk

  25. Slide 25: Sucampo Evolution

    Slide 25: Sucampo Evolution

    Sucampo Evolution $ sucAMPO_ 989 1994 996 R-Tech Ueno, Ltd SCULA hiko Kuno and Dr. Ueno ‘established found RTU Ueno 59) Japan fate rte become Sucar 1007 2008 1009 204 2012 2013 Initia! ITIZA AMITIZA AMITIZA AMITIZA Public come approved for approved for Offering forcicin — Sucampo AG ‘IC inthe Switze

Source: SEC EDGAR · 8-K filed Dec 2, 2015

More decks from Sucampo Pharmaceuticals Inc